Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Eli Lilly Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (76)
Cancellation by sponsor (55)
Australian Public Assessment Report (AusPAR) (19)
Prescription medicine registration (16)
Designation or determination (4)
Prescription medicine decision summary (3)
Prescription medicine evaluation (3)

Date

2024 (23)
2023 (22)
2022 (15)
2021 (10)
2020 (4)
2019 (34)
2018 (14)
2017 (1)
2016 (2)
2015 (7)
2014 (2)
2013 (4)
2012 (1)
2011 (2)
2010 (1)
2008 (4)
2007 (3)
2006 (1)
2004 (7)
2003 (1)
2002 (2)
1999 (5)
1998 (1)
1996 (2)
1993 (1)
1992 (4)
1991 (3)

Results for "[search-keyword]"

Search

Sponsor content

176 result(s) found, displaying 81 to 90

OLUMIANT baricitinib 4 mg film-coated tablet blister pack (277917)

23 January 2018

ARTG

Australian Register of Therapeutic Goods (ARTG) information for OLUMIANT baricitinib 4 mg film-coated tablet blister pack.
GEMZAR gemcitabine 1g (as hydrochloride) powder for injection, vial Cancelled under Section 30(1)(c) of the Act

25 November 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
GEMZAR gemcitabine 200mg (as hydrochloride) powder for injection, vial Cancelled under Section 30(1)(c) of the Act

25 November 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
ZYPREXA olanzapine 15mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 September 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
ZYPREXA olanzapine 20mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 September 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
TRULICITY (Eli Lilly Australia Pty Ltd)

19 July 2019

Prescription medicine registration

Active ingredients: dulaglutide (rch).
AusPAR: Baricitinib

21 March 2019

Australian Public Assessment Report (AusPAR)

Australian Public Assessment for Baricitinib
LANZEK ZYDIS olanzapine 5mg wafer blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
LANZEK ZYDIS olanzapine 10mg wafer blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
LANZEK ZYDIS olanzapine 15mg wafer blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.